Colorectal cancer is a leading cause of cancer mortality. The investigation on signaling pathways in colorectal tumors has contributed to the identification of specific molecular markers of response to targeted agents. In this review we discuss well-established and potential predictive biomarkers of benefit with epidermal growth factor receptor (EGFR) inhibitors. Data derived from several phase III trials has indicated that KRAS mutations can be considered a highly specific negative biomarker of response to anti-EGFR monoclonal antibodies. We'll also discuss other molecular aberrations in pathways of EGFR such as BRAF, NRAS, PIK3CA mutations and PTEN loss will. Moreover, biomarkers of efficacy to classical chemotherapeutic agents as well as recent advances regarding high-throughput technologies and circulating tumor cells will also be considered. Validation of many biomarkers in prospective clinical trials is urgently warranted. Copyright © 2011 Aran Ediciones, s. l.
|Journal||Revisiones en Cancer|
|Publication status||Published - 20 Jun 2011|
- Colorectal cancer
- KRAS mutations
- Targeted therapy